Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 147Melanoma 122Breast Neoplasms 98Squamous Cell Carcinoma of Head and Neck 96Triple Negative Breast Neoplasms 85Lung Neoplasms 64Neoplasm Metastasis 53Carcinoma, Renal Cell 49Neoplasms 46Head and Neck Neoplasms 46Colorectal Neoplasms 41Ovarian Neoplasms 38Carcinoma, Transitional Cell 36Carcinoma, Hepatocellular 36Pancreatic Neoplasms 35Urinary Bladder Neoplasms 34Recurrence 33Stomach Neoplasms 32Glioblastoma 30Brain Neoplasms 28Sarcoma 26Endometrial Neoplasms 25Prostatic Neoplasms 23Hodgkin Disease 22Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Carcinoma, Squamous Cell 19Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Multiple Myeloma 16

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1erdafitinib 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Muscle Invasive Bladder Urothelial Carcinoma × pembrolizumab × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Hoosier Cancer Research Network

Phase 2 Recruiting
47 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡